Plasma complement component 4 increases in patients with major depressive disorder

Código QR

Plasma complement component 4 increases in patients with major depressive disorder

Jinxue Wei,* Ye Liu,* Liansheng Zhao, Xiao Yang, Peiyan Ni, Yingcheng Wang, Tao Li, Xiaohong Ma Psychiatric Laboratory and Mental Health Center, Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China *These authors contributed equally to this work Abstract: Elevati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei J, Liu Y, Zhao L, Yang X, Ni P, Wang Y, Li T, Ma X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	major depressive disorder complement component 4 inflammatory factors Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/fdb3bdda310f47f89b58f411a6db34eb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
por: Yoshimura R, et al.
Publicado: (2019)

Identification of Gene Co-Expression Modules and Core Genes Related to Immune Disorders in Major Depression Disorder
por: Zhang L, et al.
Publicado: (2021)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue T, et al.
Publicado: (2020)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Clinical Response of Major Depressive Disorder Patients With Suicidal Ideation to Individual Target-Transcranial Magnetic Stimulation
por: Nailong Tang, et al.
Publicado: (2021)

Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
por: Wang M, et al.
Publicado: (2019)

Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
por: Bo Q, et al.
Publicado: (2019)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
por: Ran S, et al.
Publicado: (2020)

Disrupted Brain Entropy And Functional Connectivity Patterns Of Thalamic Subregions In Major Depressive Disorder
por: Xue SW, et al.
Publicado: (2019)

Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis
por: Lindsay M. Melhuish Beaupre, et al.
Publicado: (2021)

Identifying factors associated with the hospital readmission rate among patients with major depressive disorder
por: Sharareh Parami, et al.
Publicado: (2021)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Plasma disturbance of phospholipid metabolism in major depressive disorder by integration of proteomics and metabolomics
por: Gui SW, et al.
Publicado: (2018)

Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
por: F Kheirkhah, et al.
Publicado: (2010)

Childhood Emotional Neglect Is Associated With Low Social Support in Chinese Patients With Major Depressive Disorder
por: Xuemei Qin, et al.
Publicado: (2021)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li G, et al.
Publicado: (2016)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018)

Self-stigma in borderline personality disorder – cross-sectional comparison with schizophrenia spectrum disorder, major depressive disorder, and anxiety disorders
por: Grambal A, et al.
Publicado: (2016)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Borjanka Batinic, et al.
Publicado: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Plasma proteomic data in bipolar II disorders and major depressive disorders
por: Hyunju Lee, et al.
Publicado: (2021)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
por: Miguel A. Ortega, et al.
Publicado: (2021)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
por: Fuquan Zhang, et al.
Publicado: (2021)

Association Analysis Between Catechol-O-Methyltransferase Expression and Cognitive Function in Patients with Schizophrenia, Bipolar Disorder, or Major Depression
por: Ni P, et al.
Publicado: (2021)

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
por: Bian Z, et al.
Publicado: (2021)

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data
por: Solem CT, et al.
Publicado: (2016)

Impact of Expression and Genetic Variation of microRNA-34b/c on Cognitive Dysfunction in Patients with Major Depressive Disorder
por: Sun N, et al.
Publicado: (2020)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Potential Biomarkers for Diagnosing Major Depressive Disorder Patients with Suicidal Ideation
por: Bai S, et al.
Publicado: (2021)

Prevalence of Major Depressive Disorder and Correlates of Thoughts of Death, Suicidal Behaviour, and Death by Suicide in the Geriatric Population—A General Review of Literature
por: Gloria Obuobi-Donkor, et al.
Publicado: (2021)

EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
por: Muhammad Siddique Kakar, et al.
Publicado: (2020)

Associations Between Tenascin-C and Testosterone Deficiency in Men with Major Depressive Disorder: A Cross-Sectional Retrospective Study
por: Peng R, et al.
Publicado: (2021)